The synthesis of 18-membered macrocyclic ligands containing saturated amine and either pyridine or furan heterocyclic units is described. The protonation equilibria were studied by potentiometric titrations in which four protonation steps were observed for each ligand in the pH ranges 3-12. The protonation mechanism of these macrocyclic ligands was determined from potentiometric titrations followed by NMR and is consistent with protonation of only the saturated amine groups in the pH range studied. The formation constants for complexes of pyo2[18]dieneN6 with Ca(II), Mg(II), Mn(II), Cu(II), Zn(II), Cd(II), La(III), and Gd(III), determined potentiometrically, follow the order of the Irving-Williams series and are consistent with 1:1 metal ion binding. Furthermore, py02[18]dieneN6 binds as well or better than its saturated homolog, [ 18]aneN6. In contrast, furo2[l 8]aneN402 doesnot bind effectively in comparison to the saturated homolog, trans-[ 18]aneN402. The difference in binding may be due to a combination of enthalpic (polarity of ligating groups and steric strain of the ligand) and entropic (rigidity of the ligand) contributions.
(2S,3R)-N-[2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (7a, TC-5619), a novel selective agonist of the α7 neuronal nicotinic acetylcholine receptor, has been identified as a promising drug candidate for the treatment of cognitive impairment associated with neurological disorders. 7a demonstrated more than a thousand-fold separation between the affinities for the α7 and α4β2 receptor subtypes and had no detectable effects on muscle or ganglionic nicotinic receptor subtypes, indicating a marked selectivity for the central nervous system over the peripheral nervous system. Results obtained from homology modeling and docking explain the observed selectivity. 7a had positive effects across cognitive, positive, and negative symptoms of schizophrenia in animal models and was additive or synergistic with the antipsychotic clozapine. Compound 7a, as an augmentation therapy to the standard treatment with antipsychotics, demonstrated encouraging results on measures of negative symptoms and cognitive dysfunction in schizophrenia and was well tolerated in a phase II clinical proof of concept trial in patients with schizophrenia.
Diversification of essential nicotinic cholinergic pharmacophoric elements, i.e., cationic center and hydrogen bond acceptor, resulted in the discovery of novel potent α4β2 nAChR selective agonists comprising a series of N-acyldiazabicycles. Core characteristics of the series are an exocyclic carbonyl moiety as a hydrogen bond acceptor and endocyclic secondary amino group. These features are positioned at optimal distance and with optimal relative spatial orientation to provide near optimal interactions with the receptor. A novel potent and highly selective α4β2 nAChR agonist 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (56, TC-6683, AZD1446) with favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and is currently being progressed to phase 2 clinical trials as a treatment for Alzheimer's disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.